H
Hiroshi Nakashima
Researcher at Brigham and Women's Hospital
Publications - 33
Citations - 1357
Hiroshi Nakashima is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Oncolytic virus & Immune system. The author has an hindex of 15, co-authored 33 publications receiving 890 citations. Previous affiliations of Hiroshi Nakashima include The Ohio State University Wexner Medical Center & Brigham and Women's Faulkner Hospital.
Papers
More filters
Journal ArticleDOI
Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
Franz Ricklefs,Franz Ricklefs,Quazim A. Alayo,Harald Krenzlin,Ahmad Bakur Mahmoud,Ahmad Bakur Mahmoud,Maria C. Speranza,Maria C. Speranza,Hiroshi Nakashima,Josie Hayes,Kyungheon Lee,Leonora Balaj,Carmela Passaro,Arun K. Rooj,Susanne Krasemann,Bob S. Carter,Clark C. Chen,Tyler Steed,Jeffrey M. Treiber,Scott J. Rodig,Katherine Yang,Ichiro Nakano,Hakho Lee,Ralph Weissleder,Xandra O. Breakefield,Jakub Godlewski,Manfred Westphal,Katrin Lamszus,Gordon J. Freeman,Agnieszka Bronisz,Sean E. Lawler,E. Antonio Chiocca +31 more
TL;DR: Results suggest that PD-L1 on EVs may be another mechanism for glioblastoma to suppress antitumor immunity and support the potential of EVs as biomarkers in tumor patients.
Journal ArticleDOI
Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial.
E. Antonio Chiocca,E. Antonio Chiocca,John S. Yu,Rimas V. Lukas,Rimas V. Lukas,Isaac H. Solomon,Keith L. Ligon,Hiroshi Nakashima,Daniel Triggs,David A. Reardon,Patrick Y. Wen,Brittany M. Stopa,Ajay Naik,Jeremy Rudnick,Jethro Hu,Priya Kumthekar,Bakhtiar Yamini,Jill Buck,Nathan Demars,John A. Barrett,Arnold Gelb,John Zhou,Francois Lebel,Laurence J.N. Cooper,Laurence J.N. Cooper +24 more
TL;DR: This phase 1 trial showed acceptable tolerability of regulated hIL-12 with encouraging preliminary results, and inflammatory infiltrates in patients undergoing resection of recurrent high-grade glioma support an immunological antitumor effect of h IL-12.
Journal ArticleDOI
Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.
Hiroaki Uchida,Hiroaki Uchida,Marco Marzulli,Kenji Nakano,Kenji Nakano,Kenji Nakano,William F. Goins,Janet Chan,Chang Sook Hong,Lucia Mazzacurati,Ji Young Yoo,Amy Haseley,Hiroshi Nakashima,Hyunjung Baek,Heechung Kwon,Izumi Kumagai,Masahide Kuroki,Balveen Kaur,E. Antonio Chiocca,Paola Grandi,Justus B. Cohen,Joseph C. Glorioso +21 more
TL;DR: An approach to HSV retargeting that is effective in a glioma model and may be applicable to the treatment of a broad range of tumor types is described.
Journal ArticleDOI
Arming an oncolytic herpes simplex virus Type 1 with a single chain fragment variable antibody against PD-1 for experimental glioblastoma therapy.
Carmela Passaro,Quazim A. Alayo,Isabel DeLaura,John McNulty,Korneel Grauwet,Hirotaka Ito,Vivek Bhaskaran,Marco Mineo,Sean E. Lawler,Khalid Shah,Maria C. Speranza,Maria C. Speranza,William F. Goins,Eric McLaughlin,Soledad Fernandez,David A. Reardon,Gordon J. Freeman,E. Antonio Chiocca,Hiroshi Nakashima +18 more
TL;DR: In situ NG34scFvPD-1 treatment improved the survival with a tail of durable survivorship in 2 syngeneic immunocompetent mouse models of GBM with evidence for antitumor memory.
Journal ArticleDOI
Interferon-stimulated gene 15 (ISG15) and ISG15-linked proteins can associate with members of the selective autophagic process, histone deacetylase 6 (HDAC6) and SQSTM1/p62.
TL;DR: It is shown that the C-terminal LRLRGG of ISG15 interacts with the binder of ubiquitin zinc finger (BUZ) domain of histone deacetylase 6 (HDAC6) that marks proteins for interaction with HDAC6 and p62 upon forced stressful conditions likely as a step toward autophagic clearance.